HC Wainwright Has Pessimistic View of Metagenomi Q2 Earnings

Metagenomi, Inc. (NASDAQ:MGX - Free Report) - Investment analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for shares of Metagenomi in a research note issued to investors on Tuesday, May 27th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.54) per share for the quarter, down from their prior estimate of ($0.51). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Metagenomi's current full-year earnings is ($2.46) per share. HC Wainwright also issued estimates for Metagenomi's Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.41) EPS and FY2026 earnings at ($2.91) EPS.

Metagenomi (NASDAQ:MGX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.06). Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%. The firm had revenue of $4.13 million during the quarter, compared to the consensus estimate of $8.75 million.

Several other research analysts have also issued reports on the company. Wall Street Zen lowered Metagenomi from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Wells Fargo & Company reaffirmed an "overweight" rating and set a $16.00 target price (down from $20.00) on shares of Metagenomi in a research report on Wednesday, May 14th. Finally, Chardan Capital lowered their target price on Metagenomi from $13.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $13.00.

Metagenomi Stock Performance

Shares of MGX traded down $0.09 during trading hours on Thursday, reaching $1.69. The stock had a trading volume of 260,689 shares, compared to its average volume of 790,750. Metagenomi has a 12 month low of $1.23 and a 12 month high of $6.90. The stock has a market capitalization of $63.19 million, a PE ratio of -0.80 and a beta of -0.65. The company's 50-day moving average is $1.56 and its two-hundred day moving average is $2.24.

Institutional Trading of Metagenomi

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in Metagenomi by 73.8% during the 4th quarter. Geode Capital Management LLC now owns 587,421 shares of the company's stock valued at $2,121,000 after purchasing an additional 249,390 shares during the last quarter. Norges Bank bought a new position in shares of Metagenomi during the 4th quarter worth approximately $1,300,000. Peapod Lane Capital LLC bought a new position in shares of Metagenomi during the 4th quarter worth approximately $1,268,000. Northern Trust Corp lifted its position in shares of Metagenomi by 185.6% during the 4th quarter. Northern Trust Corp now owns 223,934 shares of the company's stock worth $808,000 after buying an additional 145,536 shares in the last quarter. Finally, Good Life Advisors LLC bought a new position in shares of Metagenomi during the 4th quarter worth approximately $451,000.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.